CHEK2 Alterations in Pediatric Malignancy: A Single-Institution Experience

Background: Approximately 10% of pediatric malignancies are secondary to germline alterations in cancer-predisposing genes. Checkpoint kinase 2 (CHEK2) germline loss-of-function variants have been reported in pediatric cancer patients, but clinical phenotypes and outcomes are poorly described. We present our single-institution experience of pediatric oncology patients with CHEK2 germline alterations, including clinical presentations and outcomes. Methods: Pediatric oncology patients with CHEK2 germline alterations were identified among those assessed by clinical or translational research at the Institute for Genomic Medicine at Nationwide Children’s Hospital. A chart review of disease course was conducted on identified patients. Results: We identified 6 patients with germline CHEK2 variants from a cohort of 300 individuals, including 1 patient with concurrent presentation of Burkitt lymphoma and neuroblastoma, 3 patients with brain tumors, 1 patient with Ewing sarcoma, and 1 patient with myelodysplastic syndrome. Three patients had a family history of malignancies. Four patients were in remission; one was undergoing treatment; one patient had developed treatment-related meningiomas. We review prior data regarding CHEK2 variants in this population, challenges associated with variant interpretation, and genetic counseling for individuals with CHEK2 variants. Conclusions: CHEK2 germline loss-of-function alterations occur in patients with a variety of pediatric tumors. Larger multicenter studies will improve our understanding of the incidence, phenotype, and molecular biology of CHEK2 germline variants in pediatric cancers.

[1]  R. Scott,et al.  Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants , 2022, Journal of the National Cancer Institute.

[2]  L. Godley,et al.  Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies , 2022, Current Hematologic Malignancy Reports.

[3]  H. van Attikum,et al.  CHEK2 variants: linking functional impact to cancer risk. , 2022, Trends in cancer.

[4]  E. V. Van Allen,et al.  Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes , 2022, American journal of human genetics.

[5]  Xueen Li,et al.  The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation , 2022, Frontiers in Genetics.

[6]  A. Sokolenko,et al.  Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability , 2022, Breast Cancer Research and Treatment.

[7]  H. Takada,et al.  Cancer-Predisposition Genetic Analysis in Children with Brain Tumors Treated at a Single Institution in Japan , 2021, Oncology.

[8]  R. Eeles,et al.  Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk , 2021, Cancer research.

[9]  E. Sokol,et al.  Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. M. Fernández,et al.  Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care , 2021, Cancers.

[11]  P. Leavey,et al.  Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report , 2021, Journal of Clinical Oncology.

[12]  A. Stenman,et al.  Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma , 2021, Endocrine-related cancer.

[13]  P. Pelicci,et al.  Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm. , 2021, American journal of human genetics.

[14]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[15]  A. Goldenberg,et al.  Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma , 2021, JCO precision oncology.

[16]  P. Kleiblova,et al.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate , 2020, Cells.

[17]  L. Forétova,et al.  Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes , 2020, Biomedicines.

[18]  C. Lázaro,et al.  Comprehensive analysis and ACMG‐based classification of CHEK2 variants in hereditary cancer patients , 2020, Human mutation.

[19]  Samantha N. McNulty,et al.  Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications , 2020, Brain pathology.

[20]  P. Cin,et al.  Malignant tumours of the uterus and ovaries with Mullerian and germ cell or trophoblastic components have a somatic origin and are characterised by genomic instability  , 2020, Histopathology.

[21]  G. Vassal,et al.  Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. , 2020, The New England journal of medicine.

[22]  F. Cheng,et al.  Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors , 2020, Nature Communications.

[23]  F. Zaker,et al.  Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes. , 2020, Hematology/oncology and stem cell therapy.

[24]  A. Chiriță-Emandi,et al.  Challenges in reporting pathogenic/potentially pathogenic variants in 94 cancer predisposing genes - in pediatric patients screened with NGS panels , 2020, Scientific Reports.

[25]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[26]  J. Biegel,et al.  Germline genetic landscape of pediatric central nervous system (CNS) tumors. , 2019, Neuro-oncology.

[27]  D. Kodetová,et al.  Somatic genetic alterations in a large cohort of pediatric thyroid nodules , 2019, Endocrine connections.

[28]  A. Papavassiliou,et al.  Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system , 2019, Human mutation.

[29]  J. Reis-Filho,et al.  The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers , 2019, JNCI cancer spectrum.

[30]  P. Stadler,et al.  Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma , 2019, Nature Communications.

[31]  James R. Anderson,et al.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.

[32]  V. Menon,et al.  Factors predicting reclassification of variants of unknown significance. , 2018, American journal of surgery.

[33]  P. Radice,et al.  Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of CHEK2 in Wilms tumour susceptibility , 2018, Oncotarget.

[34]  M. Czyżewska,et al.  Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. , 2018, Leukemia research.

[35]  Colin C Pritchard,et al.  Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations , 2018, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[36]  C. Vnencak-Jones,et al.  The impact of variant classification on the clinical management of hereditary cancer syndromes , 2018, Genetics in Medicine.

[37]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[38]  S. Gruber,et al.  Germline Genetic Features of Young Individuals With Colorectal Cancer. , 2017, Gastroenterology.

[39]  James M Ford,et al.  Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk , 2017, Genetics in Medicine.

[40]  R. Davis,et al.  Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. , 2017, Blood.

[41]  Qing-Rong Chen,et al.  A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.

[42]  T. Merchant,et al.  Results of COG ACNS0331: A Phase III Trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with Chemotherapy in Average-Risk Medulloblastoma: A Report from the Children's Oncology Group , 2016 .

[43]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[44]  J. Mora,et al.  Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression , 2016, Oncotarget.

[45]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[46]  P. Souček,et al.  Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma , 2015, PloS one.

[47]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[48]  J. Biegel,et al.  Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. , 2014, Cancer genetics.

[49]  G. Gao,et al.  Genetic association of CHEK2, GSTP1, and ERCC1 with glioblastoma in the Han Chinese population , 2014, Tumor Biology.

[50]  Nazneen Rahman,et al.  Realizing the promise of cancer predisposition genes , 2014, Nature.

[51]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[52]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[53]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[54]  Mark D. Johnson,et al.  Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma. , 2012, Neoplasia.

[55]  N. Pavletich,et al.  Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. , 2009, Molecular cell.

[56]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[57]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[58]  Patricia L. Harris,et al.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts , 2007, International journal of cancer.

[59]  Johanna Schleutker,et al.  CHEK2 mutations in primary glioblastomas , 2005, Journal of Neuro-Oncology.

[60]  Y. Hayashi,et al.  Aberrations of the CHK2 gene are rare in pediatric solid tumors. , 2005, International journal of molecular medicine.

[61]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[62]  H. Piwnica-Worms,et al.  Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. , 2003, Molecular cancer research : MCR.

[63]  E. Appella,et al.  Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription , 2002, The EMBO journal.

[64]  M. Nakanishi,et al.  Role of Human Cds1 (Chk2) Kinase in DNA Damage Checkpoint and Its Regulation by p53* , 1999, The Journal of Biological Chemistry.